Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,531.00    1.00 (0.07%)
Bid:
1,531.00
Ask:
1,532.00
Spread: 1.00 (0.065%)
Market Cap: £3.22b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

Director/PDMR Shareholding

10 Apr 2025 14:36

RNS Number : 5612E
Hikma Pharmaceuticals Plc
10 April 2025
Β 

Β 

Hikma Pharmaceuticals PLC - Discretionary Share Awards

Β 

LONDON, 10 April 2025: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) (LEI: 549300BNS685UXH4JI75) announces that the Remuneration Committee made the following conditional awards under the Hikma Pharmaceuticals PLC 2023 Long Term Incentive Plan (the "LTIP") and the 2023 Deferred Bonus Plan (the "DBP") to Persons Discharging Managerial Responsibility ("PDMRs") of the Company. No consideration was paid for the grant of the awards.

Awards under the LTIP were made on 9 April 2025 based on a price of Β£18.81 per Ordinary Share (being the average mid-market Ordinary Share price for the 5-working day period prior to 9 April 2025, in accordance with the LTIP rules) (the "LTIP Awards"). All LTIP Awards are subject to the continued employment of the PDMR and malus and clawback provisions.

LTIP Performance Share Plan ("PSP") Awards are subject to the satisfaction of performance conditions set by the Remuneration Committee of the Company. The LTIP (PSP) Awards will normally vest on the later of the third anniversary of the date of grant and the determination of the performance conditions. The LTIP (PSP) Awards are then subject to an additional two-year holding period.

LTIP (Conditional) Awards will normally vest on the second anniversary of the date of grant.

Awards under the DBP were made on 9 April 2025 based on a price of Β£18.81 per Ordinary Share (being the average mid-market Ordinary Share price for the 5-working day period prior to 9 April 2025, in accordance with the DBP rules) (the "DBP Awards"). The vesting of the DBP Awards is subject to the continued employment of the PDMRs, and malus and clawback provisions. The DBP Awards will normally vest on the third anniversary of the date of grant.

Β 

This notification is made under Article 19(1) of the EU Market Abuse Regulation 596/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"). The information set out below is provided in accordance with the requirements of Article 19(3) of MAR.

Β 

Notification and public disclosure of transactions by persons discharging managerial responsibilities

Said Darwazah

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Said Darwazah

2

Reason for the notification

a)

Position/status

Executive Chairman

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Β 

Grant of awards under the LTIP and DBP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP (PSP) Award: 128,501

Nil

DBP Award: 30,783

d)

Aggregated information

Price(s): Nil

Volume(s): 159,284

e)

Date of the transaction

9 April 2025

f)

Place of the transaction

Outside a trading venue

Riad Mishlawi

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Riad Mishlawi

2

Reason for the notification

a)

Position/status

Chief Executive Officer

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Β 

Grant of awards under the LTIP and DBP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP (PSP) Award: 148,270

Nil

DBP Award: 30,582

d)

Aggregated information

Price(s): Nil

Volume(s): 178,852

e)

Date of the transaction

9 April 2025

f)

Place of the transaction

Outside a trading venue

Mazen Darwazah

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Mazen Darwazah

2

Reason for the notification

a)

Position/status

Executive Vice Chairman

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Β 

Grant of awards under the LTIP and DBP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP (PSP) Award: 102,554

Nil

DBP Award: 25,864

d)

Aggregated information

Price(s): Nil

Volume(s): 128,418

e)

Date of the transaction

9 April 2025

f)

Place of the transaction

Outside a trading venue

Bassam Kanaan

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Bassam Kanaan

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Β 

Grant of awards under the LTIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP (PSP) Award: 73,559

d)

Aggregated information

Price(s): Nil

Volume(s): 73,559

e)

Date of the transaction

9 April 2025

f)

Place of the transaction

Outside a trading venue

Khalid Nabilsi

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Khalid Nabilsi

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Β 

Grant of awards under the LTIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP (PSP) Award: 73,620

d)

Aggregated information

Price(s): Nil

Volume(s): 73,620

e)

Date of the transaction

9 April 2025

f)

Place of the transaction

Outside a trading venue

Susan Ringdal

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Susan Ringdal

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Β 

Grant of awards under the LTIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP (PSP) Award: 38,760

d)

Aggregated information

Price(s): Nil

Volume(s): 38,760

e)

Date of the transaction

9 April 2025

f)

Place of the transaction

Outside a trading venue

Hussein Arkhagha

Β 1

Β Details of the person discharging managerial responsibilities / person closely associated

Β a)

Β Name

Β Hussein Arkhagha

Β 2

Β Reason for the notification

Β a)

Β Position/status

Β PDMR

Β b)

Initial notification /Amendment

Β Initial notification

Β 3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Β a)

Β Name

Β Hikma Pharmaceuticals PLC

Β b)

Β LEI

Β 549300BNS685UXH4JI75

Β 4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Β a)

Description of the financial instrument, type of instrument and identification code

Β Description: Ordinary shares of 10 pence each (Shares)

Β ID Code: GB00B0LCW083

Β b)

Nature of the transaction

Β 

Β Grant of awards under the LTIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP (PSP) Award: 46,913

d)

Aggregated information

Price(s): Nil

Volume(s): 46,913

e)

Date of the transaction

9 April 2025

f)

Place of the transaction

Outside a trading venue

Bill Larkins

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Bill Larkins

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Β 

Grant of awards under the LTIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP (PSP) Award: 52,497

d)

Aggregated information

Price(s): Nil

Volume(s): 52,497

e)

Date of the transaction

9 April 2025

f)

Place of the transaction

Outside a trading venue

Julie Hill

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Julie Hill

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Β 

Grant of awards under the LTIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP (PSP) Award: 29,501

Nil

LTIP (Conditional) Award: 579

d)

Aggregated information

Price(s): Nil

Volume(s): 30,080

e)

Date of the transaction

9 April 2025

f)

Place of the transaction

Outside a trading venue

Hafrun Fridriksdottir

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Hafrun Fridriksdottir

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Β 

Grant of awards under the LTIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP (PSP) Award: 57,825

d)

Aggregated information

Price(s): nil

Volume(s): 57,825

e)

Date of the transaction

9 April 2025

f)

Place of the transaction

Outside a trading venue

Β 

Β 

Helen Middlemist

Group Company Secretary+44 (0) 20 7399 2760

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
DSHBXGDSSXBDGUG
Date   Source Headline
25th Apr 20247:00 amRNSTrading Statement
17th Apr 202410:42 amRNSDirector/PDMR Shareholding
15th Apr 20244:43 pmRNSHikma appoints new President of Generics business
11th Apr 202410:58 amRNSDirector/PDMR Shareholding
2nd Apr 20249:50 amRNSBlock listing Interim Review
22nd Mar 20249:21 amRNSAnnual Financial Report and Notice of AGM
13th Mar 20249:42 amRNSDirector/PDMR Shareholding
7th Mar 20241:52 pmRNSDirector/PDMR Shareholding
1st Mar 202410:17 amRNSTotal Voting Rights
22nd Feb 20247:00 amRNSFinal Results
5th Feb 20248:46 amRNSNotice of Results
1st Feb 20246:22 pmRNSAgreement in Principle for US Opioid Settlement
1st Feb 202412:08 pmRNSTotal Voting Rights
2nd Jan 20243:24 pmRNSTotal Voting Rights
29th Dec 20237:00 amRNSCompany Secretary Change
1st Dec 20237:00 amRNSTotal Voting Rights
2nd Nov 20237:00 amRNSTrading Statement
2nd Oct 202310:13 amRNSBlock listing Interim Review
2nd Oct 202310:04 amRNSTotal Voting Rights
1st Sep 20237:00 amRNSTotal Voting Rights
31st Aug 20234:14 pmRNSDirector/PDMR Shareholding
11th Aug 20232:00 pmRNSDirector/PDMR Shareholding
10th Aug 20234:53 pmRNSDirector/PDMR Shareholding
3rd Aug 20237:00 amRNSHalf-year Report
17th Jul 20239:11 amRNSNotice of Results
14th Jun 202310:03 amRNSHolding(s) in Company
8th Jun 202310:25 amRNSDirector/PDMR Shareholding
31st May 20233:20 pmRNSDirector/PDMR Shareholding
23rd May 20234:14 pmRNSHolding(s) in Company
17th May 20239:56 amRNSDirector/PDMR Shareholding
2nd May 202310:53 amRNSTotal Voting Rights
28th Apr 20233:25 pmRNSResult of AGM
28th Apr 20237:00 amRNSTrading Statement
24th Apr 20234:15 pmRNSDirector/PDMR Shareholding
12th Apr 20237:00 amRNSDirectorate Change
3rd Apr 20239:27 amRNSBlock listing Interim Review
3rd Apr 20239:19 amRNSTotal Voting Rights
16th Mar 202310:17 amRNSAnnual Financial Report and Notice of AGM
2nd Mar 20239:30 amRNSTotal Voting Rights
23rd Feb 20237:00 amRNSFinal Results
17th Feb 202310:20 amRNSHolding(s) in Company
7th Feb 20239:36 amRNSNotice of Results
1st Feb 202310:18 amRNSTotal Voting Rights
18th Jan 202310:16 amRNSDirector/PDMR Shareholding
18th Jan 20239:39 amRNSHolding(s) in Company
17th Jan 202311:58 amRNSHolding(s) in Company
10th Jan 20233:42 pmRNSAdditional Listing
10th Jan 20239:20 amRNSDirector/PDMR Shareholding
3rd Jan 20239:23 amRNSTotal Voting Rights
3rd Jan 20237:00 amRNSHikma launches sodium oxybate in the US

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.